News iX Biopharma Ltd.

Equities

42C

SG1BD9000009

Market Closed - Singapore S.E. Other stock markets 01:23:00 26/06/2024 pm IST			5-day change	1st Jan Change
0.031 ^SGD	+3.33%		-1.90%	-30.34%

19/06	Ix Biopharma Cuts Conversion Price of 9% Convertible Bonds	MT
11/06	Singapore Shares Fall As Federal Interest Rate Cut Hopes Dim; China Mining Up 29%	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Ix Biopharma Cuts Conversion Price of 9% Convertible Bonds	19/06	MT
Singapore Shares Fall As Federal Interest Rate Cut Hopes Dim; China Mining Up 29%	11/06	MT
IX Biopharma to Raise Up to SG$5 Million from Rights Issue	11/06	MT
Singaporean Shares End Marginally Higher; Biopharma's Shares Climb 2% on Introduction of New Sublingual Wafer	12/03	MT
IX Biopharma Introduces New Sublingual Wafer	12/03	MT
IX Biopharma Ltd. Announces Development of Semaglutide Sublingual Wafer, Ixb 401, Targeting Diabetes and Obesity Markets	11/03	CI
Singapore Stocks Linger in Red; IX Biopharma's Shares Soar 12% Following Unveiling of Novel Drug Delivery System	05/03	MT
IX Biopharma Unveils Novel Drug Delivery System; Shares Surge 12%	05/03	MT
Singapore Stocks Open on Monday in Red; IX Biopharma’s Stock Plunge 9% Following Contract Termination	04/03	MT
IX Biopharma Ltd. Unveils Novel NAD Wafers At the Centre for Healthy Longevity Conference 2024	04/03	CI
IX Biopharma’s Subsidiary Issues Termination Notice for Licensing Agreement; Shares Plunge 9%	04/03	MT
IX Biopharma Stays in Red in Fiscal H1	06/02	MT
IX Biopharma Ltd. Reports Earnings Results for the Half Year Ended December 31, 2023	05/02	CI
IX Biopharma Unit Ends Wafermine Licensing Deal with Seelos Therapeutics; Shares Tumble 10%	20/11	MT
IX Biopharma Unit Launches Anti Ageing Products in US	02/23/02	MT
IX Biopharma Ltd Announces its Wholly-Owned Subsidiary, Meltmed Inc, Introduces its New Suite of Fast-Dissolving Wafer Products in United States	29/23/29	CI
Singapore Stocks Snap Losing Streak; Oxley Shares Slip 4% on Expected Losses in Fiscal H2, Fiscal 2023	22/23/22	MT
IX Biopharma Trims Losses in Fiscal H2; Shares Jump 17%	22/23/22	MT
IX Biopharma Ltd. Reports Earnings Results for the Full Year Ended June 30, 2023	21/23/21	CI
IX Biopharma Limited Unveils Development of Interferon Wafer to Complement Respiratory Viral Diseases	16/23/16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News iX Biopharma Ltd.

Equities

42C

SG1BD9000009

Summary

Filters